LCT is US-bound
Tuesday, 29 July, 2008
Auckland's diabetes transplant company Living Cell Technologies [ASX: LCT] has appointed a new CEO based in the US.
The current chief, Dr Paul Tan, will remain CEO of LCT New Zealand and will also take up the role of chief operating officer for the company.
The new CEO is Dr Robert Caspari, an LCT director and former head of Aurogen. He is based in Boulder, Colorado, and will lead development of the company from there. LCT recently listed American depository receipts on the International OTCQX, a market aimed at small to medium publicly listed companies.
Caspari has held positions with several pharma companies including Novo Nordisk, Baxter, Boehringer Mannheim, and Schering-Plough.
LCT plans a clinical trial at the Barbara Davis Centre for Diabetes in Denver next year.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
